Mesenbio, a University of York spin-out that is developing a novel treatment for arthritis created from engineered human stem cells, has raised £1.4m in an investment round co-led by DSW Ventures and NG Bio alongside grant funding from Innovate UK.

The treatment will initially target rheumatoid arthritis, an autoimmune disease that impacts nearly half a million adults and children in the UK alone, causing debilitating joint pain and inflammation of the hands, knees, elbows, ankles, and wrists.